32:44
What do we need to accomplish to cure GU malignancies by 2025? - Dean Bajorin
16:30
How do I treat CRPC in 2015? - Oliver Sartor
13:35
How do I treat metastatic RCC in 2015? - Charles J. Ryan
12:23
How do I treat advanced bladder cancer in 2015? - Walter Stadler
16:29
The next step in immunotherapy for GU malignancies - Allan J. Pantuck
17:23
Personalizing therapy for GU tumors - Alan Bryce
15:24
Addressing the needs of GU cancer survivors - Deborah Kuban
17:15
New surgical techniques - Jennifer A. Linehan
26:06
Molecular genomics of prostate cancer - Scott A. Tomlins
25:25
Biologic rationale for next-generation AR inhibitors - Mary-Ellen Taplin
20:37
Abiraterone: Prolonging survival pre-docetaxel - Charles J. Ryan
24:13
Enzalutamide: Monotherapy and combination therapy - Andrew J. Armstrong
15:42
What to do with the post-abiraterone/-enzalutamide patient? - Nicholas J. Vogelzang
20:50
Next-generation anti-androgen therapy: ARN-509 and ODM-201 - Emmanuel Antonarakis
28:18
New strategies to overcome resistance to current therapies in prostate cancer - Anna C. Ferrari
20:08
9:45 AM Radium-223: How can we optimize the use for metastatic CRPC? - Tanya B. Dorff
25:26
Radium-223 combinations: Choosing a companion drug - Oliver Sartor
20:05
Next advances in radiotherapy for prostate cancer - Seungtaek Choi
21:16
Prolonging survival in early chemo-sensitive populations - Christopher Sweeney
13:25
Does every patient need hormonal ablation? - Walter Stadler
24:57
Oligometastatic disease: What do we do now? - Oliver Sartor
08:22
A randomized, phase II trial of docetaxel and prednisone - Daniel Silbiger
08:01
Accumulation of cancer-associated fibroblasts contributes to bladder cancer - Woonyoung Choi
09:45
Use of radium-223 with chemotherapy-naïve metastatic prostate cancer - Hamid Emamekhoo
15:20
INO-5150: A PSA- and PSMA-DNA based vaccine for prostate - Zane Yang
17:13
Avatar: In vitro modeling of in vivo microenvironments - James Lim
16:56
Novel minibodies to evaluate molecular targets - Robert Reiter
21:38
How do I maintain active surveillance? - Mitchell E. Gross
24:36
5:00 PM Therapeutic vaccines: The right targets at the right times - Douglas G. McNeel
23:54
Moving Provenge to the next level - Tanya B. Dorff
20:06
Overcoming resistance to ADT: What comes next? - Anna C. Ferrari
22:27
PARP and DNA repair defects (BRCA mutations) - Karen E. Knudsen
19:07
HDAC inhibitors: What do we know and where do we go? - Wm. Keving Kelly
36:09
AR-V7 as a biomarker to identify ADT-resistant patients - Emmanuel Antonarakis
21:39
Bipolar androgen therapy - John T. Isaacs
18:40
Biology of neuroendocrine differentiation - Jiaoti Huang
17:40
How do I approach NEPC? - Andrew J. Armstrong
33:27
Novel imaging techniques - Robert Reiter
X
About
Tags